2023
Prevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients With Cancer
Kroenke K, Lam V, Ruddy K, Pachman D, Herrin J, Rahman P, Griffin J, Cheville A. Prevalence, Severity, and Co-Occurrence of SPPADE Symptoms in 31,866 Patients With Cancer. Journal Of Pain And Symptom Management 2023, 65: 367-377. PMID: 36738867, PMCID: PMC10106386, DOI: 10.1016/j.jpainsymman.2023.01.020.Peer-Reviewed Original ResearchConceptsProportion of patientsRelevant symptomsPatient characteristicsCancer typesNumeric rating scaleComposite scoreMost sociodemographic characteristicsSymptom Management ModelTypes of cancerDistribution-based methodsSymptom burdenClinical symptomsSymptom prevalenceClinical trialsHigh prevalenceMID estimatesPatientsClinical approachSociodemographic characteristicsSymptom dataSymptomsOncology encountersPrevalenceRating ScaleGood internal reliability
2012
Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal Of The National Cancer Institute 2012, 105: 25-32. PMID: 23243199, PMCID: PMC3536640, DOI: 10.1093/jnci/djs463.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyProstate cancerMedicare beneficiariesGenitourinary toxicityEarly toxicityProton radiotherapyMultivariable logistic regressionPatterns of careMain outcome measuresType of radiotherapyMedicare reimbursementClinical benefitRetrospective studyPRT patientsOutcome measuresComprehensive cohortPRT useIMRT patientsPatientsSociodemographic characteristicsRadiotherapyCancerLogistic regressionMonthsSignificant differences